MedPath

Effects of Rivastigmine on reactivity based on the cholinesterase polymorphism in Alzheimer's patients

Not Applicable
Conditions
dementia
Registration Number
JPRN-UMIN000052878
Lead Sponsor
Kobe University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
203
Inclusion Criteria

Not provided

Exclusion Criteria

Those with a Mini-Mental State Examination (MMSE)11 score <24 and those already receiving public long-term care were excluded from the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The amount of change in cognitive function (composite score) from the time of enrollment to 18 months later. The composite score is calculated from the Z-scores of the MMSE, FCSRT, logical memory, DSST, TMT, counting, and word recall tasks.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath